Zacks Research Has Negative Estimate for BMY Q3 Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Equities research analysts at Zacks Research reduced their Q3 2027 earnings estimates for shares of Bristol Myers Squibb in a research note issued to investors on Friday, October 23rd. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn $1.55 per share for the quarter, down from their previous forecast of $1.56. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.51 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s FY2027 earnings at $6.23 EPS and FY2028 earnings at $5.21 EPS.

BMY has been the subject of several other reports. Royal Bank Of Canada restated a “sector perform” rating on shares of Bristol Myers Squibb in a research report on Monday, October 19th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $76.00 price target on shares of Bristol Myers Squibb in a report on Monday, October 12th. Weiss Ratings upgraded Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Morgan Stanley reiterated an “underweight” rating and set a $41.00 price target (up from $40.00) on shares of Bristol Myers Squibb in a research report on Wednesday, October 7th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 13th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $65.50.

Bristol Myers Squibb Trading Up 0.1%

Shares of BMY stock opened at $61.56 on Tuesday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. Bristol Myers Squibb has a 52-week low of $42.52 and a 52-week high of $68.64. The company has a market capitalization of $125.75 billion, a PE ratio of 13.56, a price-to-earnings-growth ratio of 0.31 and a beta of 0.19. The business’s fifty day moving average is $63.20 and its 200 day moving average is $59.79.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Davis Asset Management L.P. bought a new stake in Bristol Myers Squibb during the second quarter worth about $27,000. Addison Advisors LLC purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter worth about $32,000. Groupe la Francaise increased its position in shares of Bristol Myers Squibb by 562.9% during the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 501 shares during the last quarter. Arlington Trust Co LLC bought a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at about $35,000. Finally, Kilter Group LLC purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at about $35,000. Institutional investors own 76.41% of the company’s stock.

Insider Activity

In other news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be given a dividend of $0.63 per share. The ex-dividend date is Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Promising cancer-drug data: Bristol Myers Squibb and partners reported that izalontamab brengitecan (Iza-Bren) doubled median progression-free survival versus chemotherapy in previously treated EGFR-mutated non-small-cell lung cancer. The drug also showed encouraging results in other solid tumors, strengthening the company’s growth pipeline. Iza-Bren lung cancer trial results
• Positive Sentiment: Breast-cancer progress: Iza-Bren reportedly reduced the risk of disease progression by as much as 38% in a Phase 3 breast-cancer trial. The results could expand the drug’s commercial opportunity and support recent strength in BMY shares. Bristol Myers Squibb cancer breakthrough
• Positive Sentiment: Analyst remains bullish despite target cut: Piper Sandler lowered its price target from $82 to $78 but maintained an “overweight” rating, implying substantial potential upside from the current trading level. Piper Sandler BMY rating
• Neutral Sentiment: Q3 earnings ahead: Investors are focused on whether growth medicines and stronger Eliquis guidance can offset declines in BMY’s legacy portfolio. The company’s valuation remains relatively modest, with a P/E ratio of 13.56, but earnings execution will be important.
• Negative Sentiment: Lower earnings estimates: Zacks Research reduced its Q3 2027 EPS forecast to $1.55 from $1.56, FY2027 estimates to $6.23 from $6.24, and FY2028 estimates to $5.21 from $5.23. Zacks retains a “Hold” rating, signaling limited near-term conviction.
• Negative Sentiment: Patent-loss risk: Analysts continue to warn that upcoming loss of exclusivity for major drugs could pressure revenue. Investors remain concerned that newer products may not fully replace declining sales quickly enough.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.